NCT01445080 2021-02-02Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LeukemiaNational Cancer Institute (NCI)Phase 1/2 Completed70 enrolled 26 charts
NCT00474929 2019-08-20Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaMayo ClinicPhase 1/2 Completed103 enrolled 12 charts